All In Biotech

Drug Trial Radar · NCT05917522

Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation

Assessment of Biomarker-Guided Calcineurin Inhibitor (CNI) Substitution In Kidney Transplantation (RTB-015)

Last checked: Nov 20, 2026Latest source record: Mar 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 800 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

800

Planned (sponsor's estimate)

Start

Dec 7, 2023

Primary completion

Jul 2027

Study completion Jul 2029

Sponsor

Sponsor type
NIH
First posted
Jun 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

800 adult first time kidney transplant recipients will be enrolled in the Observational Study and followed to evaluate their Human Leukocyte Antigen (HLA)-DR/DQ molecular mismatch (mMM) score as a risk-stratifying prognostic biomarker. Six months after transplant the study will identify those who meet the eligibility criteria for the Nested Randomized Control Trial (RCT). 300 eligible subjects will be randomized 2:1 to abatacept or Standard of care (SOC) in the randomization and followed for 18 months monitoring for safety and improvement in renal function, neurocognitive function, and a life participation patient reported outcome measure (PROM). The primary objective of the Observational Study is to test the validity of the HLA-DR/DQ mMM score as a prognostic biomarker for stratification of post-transplant alloimmune risk. Whereas the objective of the Nested RCT is to test whether a superior outcome in kidney function (primary endpoint), as well as secondary endpoints (neurocognitive function, and life participation PROM), will be achieved in patients who are transitioned from Tacrolimus (TAC) to abatacept, while maintaining efficacy (freedom from biopsy proven acute rejection).

Conditions

  • Kidney Transplant

Interventions

  • AbataceptBiological

    Injection: 125 mg/mL of a clear to slightly opalescent, colorless to pale-yellow solution in a single-dose prefilled ClickJect autoinjector

  • Standard of Care at US Transplant CentersProcedure

    Control group, remaining on SOC (Tacrolimus/ Mycophenolic Acid (MPA)/ Prednisone (Pred))

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. In the Observational Study - The occurrence of any alloimmune eventTime frame: Up to 24 months post-Kidney Transplant
  2. In the Nested Randomized Control Trial (RCT) - Renal function, measured as the difference in eGFRCKD-EPI at 24-months between groups (adjusted for renal function at randomization).Time frame: At 18 months post-randomization (24 months post-transplant)

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama School of Medicine: Transplantation

    Birmingham, Alabama · Recruiting

  • Cedars Sinai Medical Center: Transplantation

    Los Angeles, California · Recruiting

  • Ronald Reagan UCLA Medical Center: Transplantation

    Los Angeles, California · Recruiting

  • Yale University, School of Medicine: Transplantation

    New Haven, Connecticut · Recruiting

  • Johns Hopkins Hospital:Transplantation

    Baltimore, Maryland · Recruiting

  • Massachusetts General Hospital: Transplantation

    Boston, Massachusetts · Recruiting

  • Mayo Clinic Rochester: Transplantation

    Rochester, Minnesota · Recruiting

  • Washington University School of Medicine in St. Louis

    St Louis, Missouri · Recruiting

  • University of Nebraska Medical Center: Transplantation

    Omaha, Nebraska · Recruiting

  • Duke University Medical Center: Transplantation

    Durham, North Carolina · Recruiting

  • Cleveland Clinic Foundation: Transplantation

    Cleveland, Ohio · Not yet recruiting

  • University of Pennsylvania Medical Center: Transplantation

    Philadelphia, Pennsylvania · Recruiting

  • University of Pittsburgh Medical Center: Transplantation

    Pittsburgh, Pennsylvania · Recruiting

  • University of Virginia Health System: Transplantation

    Charlottesville, Virginia · Recruiting

  • University of Wisconsin School of Medicine and Public Health: Transplantation

    Madison, Wisconsin · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.